Pigmented Villonodular Synovitis Clinical Trial
Official title:
Screening of Specific Genes for Pigmented Villous Nodular Synovitis
NCT number | NCT04955535 |
Other study ID # | M201947901 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | August 3, 2020 |
Est. completion date | December 27, 2020 |
Verified date | June 2021 |
Source | Peking University Third Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study retrospectively analyzed the history of present illness of PVNS patients in our hospital. The enrolled patients were followed up by telephone to follow up their postoperative recovery and living conditions. Take the patient's pathological specimens for immunohistochemical testing, evaluate the relationship between the expression of different molecular targets, clinical manifestations and patient prognosis, and explore new molecular targets related to disease diagnosis and treatment.
Status | Completed |
Enrollment | 60 |
Est. completion date | December 27, 2020 |
Est. primary completion date | December 27, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: 1. Clinical diagnosis of pigmented villonodular synovitis. 2. Clinical diagnosis of giant cell tumor of tendon sheath Exclusion Criteria: 1. No surgical treatment. 2. There were no pathological specimens during the operation. 3. The age of the patient is less than 18 years old or more than 60 years old. 4. The operation record shows nodular type. |
Country | Name | City | State |
---|---|---|---|
China | Institute of Sports Medicine, Peking University Third Hospital, Beijing Key Laboratory of Sports Injuries, Beijing, China | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Peking University Third Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Difference of scale score between immunohistochemistry positive group and negative group | Difference of Visual Analog Score for pain between CSF-1 immunohistochemistry positive group and negative group | One week after surgery | |
Primary | Difference of Visual Analog Score for pain between TNF-a immunohistochemistry positive group and negative group | Difference of Visual Analog Score for pain between TNF-a immunohistochemistry positive group and negative group | One week after surgery | |
Primary | Difference of Visual Analog Score for pain between IL-1B immunohistochemistry positive group and negative group | Difference of Visual Analog Score for pain between IL-1B immunohistochemistry positive group and negative group | One week after surgery | |
Primary | Difference of SF-36 score between CSF-1 immunohistochemistry positive group and negative group | Difference of SF-36 score between CSF-1 immunohistochemistry positive group and negative group | One week after surgery | |
Primary | Difference of SF-36 score between TNF-a immunohistochemistry positive group and negative group | Difference of SF-36 score between TNF-a immunohistochemistry positive group and negative group | One week after surgery | |
Primary | Difference of SF-36 score between IL-1B immunohistochemistry positive group and negative group | Difference of SF-36 score between IL-1B immunohistochemistry positive group and negative group | One week after surgery | |
Secondary | Correlation between basic demographic characteristics and scale scores | Correlation between age, gender and scale score | One week after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01207492 -
Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
|
Phase 2 | |
Terminated |
NCT04938180 -
A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients
|
Phase 2 | |
Active, not recruiting |
NCT05059262 -
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
|
Phase 3 | |
Active, not recruiting |
NCT04731675 -
An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee
|
Phase 2 | |
Completed |
NCT02371369 -
Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)
|
Phase 3 | |
Completed |
NCT02471716 -
Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor
|
Phase 1/Phase 2 | |
Recruiting |
NCT05349643 -
A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT
|
Phase 2 | |
Completed |
NCT04952896 -
Clinical Study of Magnetic Resonance Imaging and Deep Learning of Joint Synovial Disease
|
||
Active, not recruiting |
NCT03069469 -
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
|
Phase 1/Phase 2 | |
Completed |
NCT01261429 -
Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT)
|
Phase 2 | |
Active, not recruiting |
NCT05804045 -
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
|
Phase 3 | |
Completed |
NCT01643850 -
MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)
|
Phase 2 |